Journal
IMMUNOLOGY AND CELL BIOLOGY
Volume 84, Issue 3, Pages 281-289Publisher
WILEY
DOI: 10.1111/j.1440-1711.2006.01441.x
Keywords
adoptive immunotherapy; bone marrow transplantation; gene therapy; neoplasm; T lymphocyte
Categories
Funding
- NCI NIH HHS [P01 CA094237, P01 CA94237] Funding Source: Medline
- NCRR NIH HHS [RR00188] Funding Source: Medline
Ask authors/readers for more resources
Adoptive T-cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein-Barr virus-associated post-transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self-antigens and success has been limited in part by inadequate persistence and expansion of transferred T cells and by tumour-evasion strategies. Adoptive immunotherapy presents the opportunity to activate, expand and genetically modify T cells outside the tolerising environment of the host and a number of strategies to optimize the cellular product, including gene modification and modulation of the host environment, in particular by lymphodepletion, have been developed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available